Structured intermittent interruption of chronic HIV infection treatment with highly active antiretroviral therapy: Effects on leptin and TNF-α

AIDS Research and Human Retroviruses

Volumn 22, Issue 4, 2006, Pages 307-314

  Montes De Oca Arjona, M ^a   Perez Cano R ^a   Garcia Juarez R ^a   Martin Aspas A ^a   Fernandez Gutierrez Del Alamo C ^a   Girón González, Jose A ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; DIDANOSINE; INDINAVIR; LAMIVUDINE; LEPTIN; LOPINAVIR; NELFINAVIR; RITONAVIR; SAQUINAVIR; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; ZIDOVUDINE;

ADIPOSE TISSUE; ADULT; ANTHROPOMETRY; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DRUG DOSE REGIMEN; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NUTRITIONAL STATUS; PRIORITY JOURNAL; SKINFOLD; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CHOLESTEROL; CHRONIC DISEASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LEPTIN; MALE; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; REFERENCE STANDARDS; RNA, VIRAL; SKINFOLD THICKNESS; TREATMENT OUTCOME; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA; VIRAL LOAD;

EID: 33646123749     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.22.307     Document Type: Article

References (47)

1. Centers for Disease Control and Prevention: HIV/AIDS surveillance report 2000. Centers for Disease Control and Prevention, Atlanta, GA, 2000.
2. Finzi D, Blankson J, Siliciano JD, et al.: Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999;5:512-517.
3. Schambelan M, Benson CA, Carr A, et al.: Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: Recommendations of an International AIDS Society-USA Panel. J Acquir Immune Defic Syndr 2002;31:257-275.
4. Mohamed-Ali V, Pinkney JH, and Coppack SW: Adipose tissue as an endocrine and paracrine organ. Int J Obes 1998;22:1145-1158.
5. Considine RV, Sinha MK, Heiman ML, et al.: Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;334:292-295.
6. Reidy SP and Weber JM: Leptin: An essential regulator of lipid metabolism. Comp Biochem Phys 2000;125:285-297.
7. Hauner H, Petruschke T, Russ M, Rohrig R, and Eckel J: Effects of tumor necrosis factor alpha (TNF-α) on glucose transport and lipid metabolism of newly differentiated human fat cells in cell cul-ture. Diabetologia 1995;38:764-771.
8. Van Harmelen V, Dicker A, Ryden M, et al.: Increased lipolysis and decreased leptin production by human omental as compared with subcutaneous preadipocytes. Diabetes 2002;51:2029-2036.
9. Montague CT, Prins JB, Sanders L, Digby JE, and O'Rahily S: Depot and sex specific differences in human leptin mRNA expression: Implications for the control of regional fat distribution. Diabetes 1997;46:342-347.
10. Hube F, Birgel M, Lee YM, and Hauner H: Expression pattern of tumor necrosis factor receptor in subcutaneous and omental human adipose tissue: Role of obesity and non-insulin dependent diabetes mellitus. Eur J Clin Invest 1999;29:672-678.
11. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, and Cooper DA: Diagnosis, prediction, and natural course of HIV protease-inhibitor- associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study. Lancet 1999;353:2093-2099.
12. Addy CL, Gavrila A, Tsiodras S, Brodovicz K, Karchmer AW, and Mantzoros CS: Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. J Clin Endocrinol Metabol 2003;88:627-636.
13. Nagy GS, Tsiodras S, Martin LD, et al.: Human immunodeficiency virus type-1 related lipoatrophy and lipohypertrophy are associated with serum concentrations of leptin. Clin Infect Dis 2003;36:795-802.
14. Kosmiski L, Kuritzkes D, Lichtenstein K, and Eckel R: Adipocyte-derived hormone levels in HIV lipodystrophy. Antiviral Ther 2003;8:9-15.
15. Vigouroux C, Maachi M, Nguyen TH, et al.: Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. AIDS 2003;17:1503-1511.
16. Liotta A, Maggio MC, Di Carlo P, et al.: Serum leptin and interleukin-6 levels in pediatric patients with HIV. J Pediatr Endocrinol Metab 2003;16:179-183.
17. Sutinen J, Hakkinen AM, Westerbacka J, et al.: Rosiglitazone in the treatment of HAART-associated lipodystrophy. A double blind placebo-controlled study. Antiviral Ther 2003;8:199-207.
18. Domingo P, Matias-Guiu X, Pujol RM, et al.: Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lypodystrophy. AIDS 1999;13:2261-2267.
19. Ledru E, Christeff N, Patey O, Truchis P, Melchior JC, and Gougeon ML: Alteration of tumor necrosis factor-a T-cell homeostasis following potent antiretroviral therapy: Contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome. Blood 2000;95:3191-3198.
20. Lori F and Lisziewicz J: Structured treatment interruptions for the management of HIV infection. JAMA 2001;286:2981-2987.
21. Miller V: Structured treatment interruptions in antiretroviral management of HIV-1. Curr Opin Infect Dis 2001;14:29-37.
22. Lori F, Foli A, and Lisziewicz J: Structured treatment interruptions as a potential alternative therapeutic regimen for HIV-infected patients: A review of recent clinical data and future prospects. J Antimicrob Chemother 2002;50:155-160.
23. Rosenberg ES, Altfeld M, Poon SH, Phillips MN, Wilkes BM, Eldridge RI, et al.: Immune control of HIV-1 after early treatment of acute infection. Nature 2000;407:523-526.
24. Lori F, Lewis MG, Xu J, et al.: Control of SIV rebound through structured treatment interruptions during early infection. Science 2000;290:1591-1593.
25. Oxenius A, Price DA, Günthard HF, et al.: Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc Natl Acad Sci USA 2002;99:13747-13752.
26. Abbas UL and Mellors JW: Interruption of antiretroviral therapy to augment immune control of chronic HIV-1 infection: Risk without reward. Proc Natl Acad Sci USA 2002;99:13777-13778.
27. Dybul M, Chun TW, Yoder C, et al: Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: Effect on virologic, immunologic and toxicity parameters. Proc Natl Acad Sci USA 2001;98:15161-15166.
28. Dybul M, Nies-Kraske E, Daucher M, et al.: Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus: Effects on drug toxicity and on immunologic and virologic parameters. J Infect Dis 2003;188:388-396.
29. Centers for Diseases Control: 1993 revised classification system for. HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992;41:17-20.
30. Klein S, Kinney J, Jeejeebhoy K, et al.: Nutrition support in clinical practice: Review of published data and recommendations for future research directions. J Parenter Enteral Nutr 1997;21: 133-155.
31. Sutinen J, Hakkinen AM, Westerbacka J, et al.: Rosiglitazone in the treatment of HAART associated lipodystrophy. A double-blind placebo-controlled study. Antiviral Ther 2003;8:199-207.
32. Fischer M, Hafner R, Schneider C, et al.: HIV RNA in plasma rebounds within days during structured treatment interruptions. AIDS 2003;17:195-199.
33. Ananworanich J, Nuesch R, Le Braz M, et al.: Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial. AIDS 2003;17:F33-F37.
34. Fagard C, Oxenius A, Gunthard H, et al.: A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. Arch Intern Med 2003;163:1220-1226.
35. García F, Plana M, Ortiz GM, et al.: The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS 2001;15:F29-F40.
36. Harrigan PR, Whaley M, and Montaner JS: Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. AIDS 1999;13:F59-F62.
37. Girón-González JA, López-Sánchez A, Elvira J, Pérez E, and Fernández-Gutiérrez C: Effect of adherence to antiretroviral therapy on CD4+ cell count, HIV-1 RNA and serum concentrations of tumor necrosis factor and its receptors. Eur J Clin Microbiol Infect Dis 2000;19:852-858.
38. Tartaglia LA and Goeddel DV: Two TNF receptors. Immunol Today 1992;13:151-153.
39. Díez-Ruiz A, Tiltz GP, Zangerle R, Baier-Bitterlich G, Wachter H, and Fuchs D: Soluble receptors for tumor necrosis factor in clinical laboratory diagnostics. Eur J Haematol 1995;54:1-8.
40. Lawn SD, Butera ST, and Folks TM: Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus infection. Clin Microbiol Rev 2001;14:753-777.
41. Sloand EM, Kumar PN, Kimi S, Chaudhuri A, Weichold FF, and Young NS: Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD4 (+) T cells and decreases their susceptibility to apoptosis in vitro and in vivo. Blood 1999;94:1021-1027.
42. Ledru E, Lecoeur H, Garcia S, Debord T, and Gougeon ML: Differential susceptibility to activation-induced apoptosis among peripheral Th1 subsets: Correlation with Bcl-2 expression and consequences for AIDS pathogenesis. J Immunol 1998;160:3194-3206.
43. Ledru E, Christeff N, Patey O, Pierre T, Melchior JC, and Gougeon ML: Alteration of tumor necrosis factor-a T-cell homeostasis following potent antiretroviral therapy: Contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome. Blood 2000;95:3191-3198.
44. Ockenga J, Widjaja A, Holtmannspotter M, Schmidt RE, and Brabant G: Bound leptin is regulated by tumour necrosis factor-alpha in HIV-infected patients: A potential mediator of wasting? AIDS 1998;12:2233-2235.
45. Oral EA, Simha V, Ruiz E, et al.: Leptin-replacement therapy for lipodystrophy. N Engl J Med 2002;346:570-578.
46. Yeni PG, Hammer SM, Carpenter CC, et al.: Antiretroviral treatment for adult HIV infection in 2002: Updated recommendations of the International AIDS Society-USA Panel. JAMA 2002;288: 222-235.
47. Tarwater PM, Parish M, and Gallant JE: Prolonged treatment interruption after immunologie response to highly active antiretroviral therapy. Clin Infect Dis 2003;37:1541-1547.